Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06514508
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Mobilization of Stem Cells With Motixafortide BL-8040 in Combination With G-CSF in Multiple Myeloma Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase Ⅲ Randomized Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blinded placebo-controlled multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy safety and pharmacokinetic and pharmacodynamic profiles of Motixafortide BL-8040 G-CSF vs placebo G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None